In an interview with Targeted Oncology, David Sallman, MD, of Moffitt Cancer Center, addresses the nuanced decision-making ...

Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...

Chemotherapy-induced myelosuppression (CIM) remains one of the most significant and underappreciated barriers to delivering ...

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...

In topline results from the phase 3 SENTRY trial, the combination of selinexor and ruxolitinib achieved a statistically ...

WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...

Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment. Paul G. Richardson, MD, director of Clinical Research and ...

Pooled evidence from 2 randomized trials and 6 observational cohorts suggests posttransplant gilteritinib maintenance may ...

Explore why community and academic oncologists collaborate, share expertise, and deliver faster, more nuanced care for complex patients. The era of the "academic master" is over. Modern oncology ...

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...

A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David ...